GSK · GSK plc

This collaboration represents a high-materiality strategic move by GSK to secure rapid, scaled commercialization of bepirovirsen — its late-stage antisense oligonucleotide for chronic hepatitis B — in China, the world’s largest endemic market for the disease. With 75 million affected individuals and functional cure established as a national treatment goal under China’s 2025–2030 Viral Hepatitis Action Plan, the partnership leverages CTTQ’s dominant hepatology footprint — including over 5,000 medical centres and one of China’s most comprehensive liver disease portfolios — to overcome typical market-access barriers. Financially, GSK retains revenue recognition via supply to CTTQ, avoiding upfront licensing fees or milestone payments but securing long-term, predictable sales flow under fixed supply terms. The agreement also embeds optionality: GSK’s right to review SBP Group’s early-stage pipeline creates a low-cost, non-exclusive pathway to expand its China-aligned R&D portfolio without commitment. Critically, the deal preserves GSK’s control over regulatory and safety responsibilities while de-risking local execution — a structure increasingly favored by global biopharma firms entering complex, highly regulated markets like China. No termination clauses, financial thresholds, or performance conditions are disclosed, indicating confidence in both regulatory timing (priority review granted April 2026) and commercial readiness.